Table 3.
Median (IQR) | 2D LVEF Beta (95% CI) | P-value* | E/e’ Beta (95% CI) | P-value* | |
---|---|---|---|---|---|
3D LVEF (%) | 49.9 (43.6, 54.6) | 2.5 (1.9, 3.1) | 0.001 | −0.3 (−0.6, −0.0) | 0.026 |
GCS (%) | −22.0 (−25.7, −18.5) | −2.4 (−3.0, −1.8) | 0.001 | 0.4 (0.1, 0.6) | 0.009 |
GLS (%) | −14.6 (−17.0, −12.3) | −2.0 (−2.8, −1.2) | <0.001 | 0.1 (−0.2, 0.5) | 0.50 |
Principal strain (%) | −25.4 (−29.0, −21.7) | −2.6 (−3.2, −1.9) | <0.001 | 0.4 (0.1, 0.7) | 0.008 |
Twist (°) | 9.0 (6.3, 12.5) | 0.7 (0.1, 1.3) | 0.019 | −0.2 (−0.4, −0.0) | 0.026 |
Torsion (°/cm) | 1.1 (0.8, 1.6) | 0.6 (0.1, 1.2) | 0.029 | −0.2 (−0.4, 0.0) | 0.071 |
P-values are based on the Wald test.
All models were adjusted for 2D LVEF or E/e’ (depending upon the outcome of interest) at baseline, age, BMI, heart rate (time-varying), systolic blood pressure (time-varying), and time since baseline (modeled non-parametrically using cubic splines).
All echocardiographic parameters were standardized based on the interquartile range at the post-anthracycline visit. An example of the interpretation is noted in Table 2.
3D indicates three-dimensional; LVEF, left ventricular ejection fraction; GCS, global circumferential strain; and GLS, global longitudinal strain.